15
Participants
Start Date
August 3, 2020
Primary Completion Date
September 3, 2022
Study Completion Date
March 3, 2025
Physical Characteristics
Body weight, height and waist circumference
Muscular Sympathetic Nervous Activity
Microneurography technique.
Cardiac Function
Echocardiography.
Heart rate
Electrocardiography
Blood pressure
Non-invasive photoplethysmography.
Blood Assessments
Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.
Muscle blood flow
Venous occlusion plethysmography
Endothelium-dependent vascular function
Brachial ultrasound
Vascular intima-media thickness
Carotid ultrasound
Physical Capacity
Cardiopulmonary exercise test
Anthracycline & Cyclophosphamide treatment scheme
Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo
Universidade Federal Fluminense
OTHER
Hospital Israelita Albert Einstein
OTHER
University of Sao Paulo General Hospital
OTHER